JP2024138268A5 - - Google Patents

Download PDF

Info

Publication number
JP2024138268A5
JP2024138268A5 JP2024095566A JP2024095566A JP2024138268A5 JP 2024138268 A5 JP2024138268 A5 JP 2024138268A5 JP 2024095566 A JP2024095566 A JP 2024095566A JP 2024095566 A JP2024095566 A JP 2024095566A JP 2024138268 A5 JP2024138268 A5 JP 2024138268A5
Authority
JP
Japan
Prior art keywords
amino acid
rtt
cell
modification
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024095566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024138268A (ja
Filing date
Publication date
Priority claimed from JP2021513765A external-priority patent/JP7596259B2/ja
Application filed filed Critical
Publication of JP2024138268A publication Critical patent/JP2024138268A/ja
Publication of JP2024138268A5 publication Critical patent/JP2024138268A5/ja
Pending legal-status Critical Current

Links

JP2024095566A 2018-05-11 2024-06-13 プログラム可能な塩基エディターシステムを用いて単一ヌクレオチド多型を編集する方法 Pending JP2024138268A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862670588P 2018-05-11 2018-05-11
US62/670,588 2018-05-11
US201862780838P 2018-12-17 2018-12-17
US62/780,838 2018-12-17
US201962817986P 2019-03-13 2019-03-13
US62/817,986 2019-03-13
JP2021513765A JP7596259B2 (ja) 2018-05-11 2019-05-11 プログラム可能な塩基エディターシステムを用いて単一ヌクレオチド多型を編集する方法
PCT/US2019/031899 WO2019217944A1 (en) 2018-05-11 2019-05-11 Methods of editing single nucleotide polymorphism using programmable base editor systems

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021513765A Division JP7596259B2 (ja) 2018-05-11 2019-05-11 プログラム可能な塩基エディターシステムを用いて単一ヌクレオチド多型を編集する方法

Publications (2)

Publication Number Publication Date
JP2024138268A JP2024138268A (ja) 2024-10-08
JP2024138268A5 true JP2024138268A5 (https=) 2025-04-25

Family

ID=68466849

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2021513765A Active JP7596259B2 (ja) 2018-05-11 2019-05-11 プログラム可能な塩基エディターシステムを用いて単一ヌクレオチド多型を編集する方法
JP2021513764A Pending JP2021523738A (ja) 2018-05-11 2019-05-11 プログラム可能な塩基エディターシステムを使用して単一ヌクレオチド多型を編集する方法
JP2024095618A Pending JP2024147545A (ja) 2018-05-11 2024-06-13 プログラム可能な塩基エディターシステムを使用して単一ヌクレオチド多型を編集する方法
JP2024095566A Pending JP2024138268A (ja) 2018-05-11 2024-06-13 プログラム可能な塩基エディターシステムを用いて単一ヌクレオチド多型を編集する方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2021513765A Active JP7596259B2 (ja) 2018-05-11 2019-05-11 プログラム可能な塩基エディターシステムを用いて単一ヌクレオチド多型を編集する方法
JP2021513764A Pending JP2021523738A (ja) 2018-05-11 2019-05-11 プログラム可能な塩基エディターシステムを使用して単一ヌクレオチド多型を編集する方法
JP2024095618A Pending JP2024147545A (ja) 2018-05-11 2024-06-13 プログラム可能な塩基エディターシステムを使用して単一ヌクレオチド多型を編集する方法

Country Status (8)

Country Link
US (2) US20230159956A1 (https=)
EP (2) EP3790963A4 (https=)
JP (4) JP7596259B2 (https=)
KR (2) KR20250133482A (https=)
CN (3) CN119587720A (https=)
AU (2) AU2019266327B2 (https=)
CA (2) CA3100034A1 (https=)
WO (2) WO2019217944A1 (https=)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230156800A (ko) 2015-03-03 2023-11-14 더 제너럴 하스피탈 코포레이션 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제
CN110612353A (zh) 2017-03-03 2019-12-24 加利福尼亚大学董事会 经由抑制性tRNAs和脱氨酶对突变进行RNA靶向
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
WO2018221685A1 (ja) 2017-05-31 2018-12-06 国立大学法人 東京大学 改変されたCas9タンパク質及びその用途
CA3073448A1 (en) 2017-08-23 2019-02-28 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
US20200370040A1 (en) * 2017-12-07 2020-11-26 Ramot At Tel-Aviv University Ltd. Treatment for parkinsonian patients with mutations in the lrrk2 gene
WO2019178427A1 (en) 2018-03-14 2019-09-19 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
WO2019222555A1 (en) 2018-05-16 2019-11-21 Arbor Biotechnologies, Inc. Novel crispr-associated systems and components
US12157760B2 (en) * 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
EP3847254A4 (en) 2018-09-07 2022-08-10 Beam Therapeutics Inc. COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM
WO2020051562A2 (en) 2018-09-07 2020-03-12 Beam Therapeutics Inc. Compositions and methods for improving base editing
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
CA3128755C (en) 2019-02-13 2024-06-04 Beam Therapeutics Inc. Compositions and methods for treating hemoglobinopathies
WO2020168088A1 (en) * 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating glycogen storage disease type 1a
CN120174005A (zh) 2019-02-13 2025-06-20 比姆医疗股份有限公司 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
CN111793627A (zh) * 2019-04-08 2020-10-20 中国科学院上海生命科学研究院 利用人工构建rna编辑酶进行rna定点编辑及相关应用
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
AU2020279751A1 (en) * 2019-05-21 2021-12-02 Beam Therapeutics Inc. Methods of editing a single nucleotide polymorphism using programmable base editor systems
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
JP7500927B2 (ja) * 2019-08-06 2024-06-18 日本製紙株式会社 プロテイン用マスキング剤
EP4034138A4 (en) 2019-09-27 2024-07-31 Beam Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
AU2020395113A1 (en) 2019-12-02 2022-06-09 Shape Therapeutics Inc. Therapeutic editing
WO2021122944A1 (en) * 2019-12-18 2021-06-24 Alia Therapeutics Srl Compositions and methods for treating retinitis pigmentosa
WO2021151085A2 (en) 2020-01-24 2021-07-29 The General Hospital Corporation Crispr-cas enzymes with enhanced on-target activity
WO2021151073A2 (en) * 2020-01-24 2021-07-29 The General Hospital Corporation Unconstrained genome targeting with near-pamless engineered crispr-cas9 variants
WO2021155166A1 (en) * 2020-01-31 2021-08-05 University Of Massachusetts A cas9-pdbd base editor platform with improved targeting range and specificity
US12416001B2 (en) * 2020-02-14 2025-09-16 Ohio State Innovation Foundation Nucleobase editors and methods of use thereof
IT202000008014A1 (it) * 2020-04-15 2021-10-15 Fond Telethon RNA guida e loro usi
US20250263752A1 (en) * 2020-04-21 2025-08-21 Aspen Neuroscience, Inc. Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
WO2021216623A1 (en) * 2020-04-21 2021-10-28 Aspen Neuroscience, Inc. Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom
EP4143315A1 (en) 2020-04-28 2023-03-08 The Broad Institute Inc. <smallcaps/>? ? ?ush2a? ? ? ? ?targeted base editing of thegene
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
WO2021231691A1 (en) * 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
WO2022015856A1 (en) * 2020-07-14 2022-01-20 The Regents Of The University Of California Compositions and methods for treating an inherited retinal disease
CA3189601A1 (en) 2020-07-24 2022-01-27 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
US20230340486A1 (en) * 2020-07-27 2023-10-26 The Children’S Hospital Of Philadelphia In utero and postnatal gene editing and therapy for treatment of monogenic diseases, including mucopolysaccharidosis type 1h and other disorders
CA3193099A1 (en) * 2020-09-24 2022-03-31 David R. Liu Prime editing guide rnas, compositions thereof, and methods of using the same
CA3196831A1 (en) 2020-09-25 2022-03-31 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
US20220145334A1 (en) * 2020-11-06 2022-05-12 Pairwise Plants Services, Inc. Compositions and methods for rna-encoded dna-replacement of alleles
CA3204073A1 (en) * 2020-12-10 2022-06-16 Apellis Pharmaceuticals, Inc. Genomic editing of complement
WO2022150651A1 (en) * 2021-01-07 2022-07-14 The Broad Institute, Inc. Dna nuclease guided transposase compositions and methods of use thereof
EP4308702A4 (en) * 2021-03-15 2025-03-05 Duke University GENERATING NEW CRISPR GENOME-EDITING AGENTS USING COMBINATORY CHEMISTRY
AU2022272250A1 (en) * 2021-05-14 2023-11-30 Beam Therapeutics Inc. Compositions and methods for treating transthyretin amyloidosis
WO2022246266A1 (en) * 2021-05-21 2022-11-24 Beam Therapeutics Inc. Base editing of transthyretin gene
CN117729926A (zh) * 2021-05-28 2024-03-19 比姆医疗股份有限公司 用于使碱基编辑器自失活的组合物和方法
IL312024A (en) * 2021-10-13 2024-06-01 Apellis Pharmaceuticals Inc Compositions and methods for genome editing the neonatal fc receptor
EP4441074A2 (en) 2021-12-03 2024-10-09 The Broad Institute, Inc. Compositions and methods for efficient in vivo delivery
US20250154479A1 (en) * 2022-01-24 2025-05-15 Toolgen Incorporated Streptococcus pyogenes-derived cas9 variant
CN114480445B (zh) * 2022-01-26 2023-06-27 西南交通大学 一种人源超氧化物歧化酶hSOD1突变体的制备及其应用
US20250304940A1 (en) * 2022-05-13 2025-10-02 Huidagene Therapeutics (Singapore) Pte. Ltd. Programmable adenine base editor and uses thereof
CN120303407A (zh) 2022-05-17 2025-07-11 恩维洛普治疗有限责任公司 用于有效体内递送的组合物和方法
CN115148281B (zh) * 2022-06-29 2023-07-14 广州源井生物科技有限公司 一种基因编辑点突变方案自动设计方法及系统
JP2025530183A (ja) * 2022-09-08 2025-09-11 ザ ユニヴァーシティ コート オブ ザ ユニヴァーシティ オブ エディンバラ レット症候群治療法
WO2024107784A2 (en) * 2022-11-15 2024-05-23 Vanderbilt University Repair of disease-associated single nucleotide variants via interallelic gene conversion
CN116286740A (zh) * 2023-02-24 2023-06-23 四川大学华西医院 碱基编辑器和引导编辑器及构建与应用
AU2024303631A1 (en) * 2023-06-15 2025-12-11 Beam Therapeutics Inc. Methods and compositions for treating alpha-1 antitrypsin deficiency
KR20260044217A (ko) * 2023-07-25 2026-04-01 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 Cas 엔도뉴클레아제 및 관련 방법
US20250059567A1 (en) * 2023-08-17 2025-02-20 The Trustees Of The University Of Pennsylvania Compositions and methods for the management and treatment of phenylketonuria
WO2025059520A1 (en) * 2023-09-15 2025-03-20 Beam Therapeutics Inc. Compositions and methods for base editing a phenylalanine hydroxylase polynucleotide
CN120813698A (zh) * 2023-09-22 2025-10-17 北京大学现代农业研究院 改进的基因组编辑方法
WO2025122725A1 (en) * 2023-12-06 2025-06-12 The Broad Institute, Inc. Methods and compositions for base editing of tpp1 in the treatment of batten disease
CN118120704B (zh) * 2024-01-30 2025-10-24 江苏集萃药康生物科技股份有限公司 一种免高脂饮食诱导的动脉粥样硬化小鼠模型的构建方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
EP1235914A2 (en) 1999-11-24 2002-09-04 Joseph Rosenecker Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
AU776576B2 (en) 1999-12-06 2004-09-16 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6689558B2 (en) 2000-02-08 2004-02-10 Sangamo Biosciences, Inc. Cells for drug discovery
AU2005274948B2 (en) 2004-07-16 2011-09-22 Genvec, Inc. Vaccines against aids comprising CMV/R-nucleic acid constructs
US8404658B2 (en) 2007-12-31 2013-03-26 Nanocor Therapeutics, Inc. RNA interference for the treatment of heart failure
MX341084B (es) 2009-11-02 2016-08-05 Univ Washington Composiciones de nucleasas terapéuticas y métodos.
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
JP7103750B2 (ja) * 2013-12-12 2022-07-20 ザ・ブロード・インスティテュート・インコーポレイテッド ゲノム編集のためのCRISPR-Cas系及び組成物の送達、使用及び治療適用
EP3155116A4 (en) * 2014-06-10 2017-12-27 Massachusetts Institute Of Technology Method for gene editing
KR20230156800A (ko) * 2015-03-03 2023-11-14 더 제너럴 하스피탈 코포레이션 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
CN109715801B (zh) 2015-12-01 2022-11-01 克里斯普治疗股份公司 用于治疗α1抗胰蛋白酶缺乏的材料和方法
US11512311B2 (en) * 2016-03-25 2022-11-29 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
EP3445853A1 (en) * 2016-04-19 2019-02-27 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
AU2017257274B2 (en) * 2016-04-19 2023-07-13 Massachusetts Institute Of Technology Novel CRISPR enzymes and systems
KR20260004568A (ko) * 2016-04-19 2026-01-08 더 브로드 인스티튜트, 인코퍼레이티드 신규한 crispr 효소 및 시스템
CN110214183A (zh) * 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
CN110352244B (zh) 2016-09-01 2023-03-21 ProQR治疗上市公司Ⅱ 化学修饰的编辑rna的单链寡核苷酸
CN107043779B (zh) * 2016-12-01 2020-05-12 中国农业科学院作物科学研究所 一种CRISPR/nCas9介导的定点碱基替换在植物中的应用
CA3073448A1 (en) * 2017-08-23 2019-02-28 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도

Similar Documents

Publication Publication Date Title
JP2024138268A5 (https=)
JP2021523739A5 (https=)
JP7698828B2 (ja) Rnaを編集する方法および組成物
JP7252328B2 (ja) Rnaを編集する方法および組成物
JP2021523736A5 (https=)
Li et al. Genome-wide analyses reveal a role of Polycomb in promoting hypomethylation of DNA methylation valleys
JP2025026840A5 (https=)
EP3371306B1 (en) Materials and methods for treatment of hemoglobinopathies
JP2022546608A5 (https=)
JP2025170240A5 (https=)
US9920363B2 (en) Constructing method of high-throughput sequencing library and use thereof
JP2024038327A5 (https=)
JP2021523737A5 (https=)
JP2022519882A5 (https=)
EP3851530A1 (en) Crispr/cas-mediated gene conversion
JP2022532139A5 (https=)
CN108351350A (zh) 使用rna指导型内切核酸酶改善基因组工程特异性的组合物和方法
JP2022545950A5 (https=)
JP2016512691A5 (https=)
JP2025102768A5 (https=)
EP3645721A1 (en) Methods for the treatment of disease with gene editing systems
Zhang et al. Comprehensive off-target analysis of dCas9-SAM-mediated HIV reactivation via long noncoding RNA and mRNA profiling
CA3136700A1 (en) Gene-editing systems for modifying a scn9a or scn10a gene and methods of use thereof
CN118871578A (zh) 用于碱基编辑的脱氨酶及其变体
JP2021522825A5 (https=)